软骨中间层蛋白1在心肌纤维化中的研究进展  

Research Progress of Cartilage Intermediate Layer Protein 1 in Myocardial Fibrosis

作　　者：孙逸伦 雷鹏[2] 白明[2] SUN Yilun;LEI Peng;BAI Ming(The First School of Clinical Medicine of Lanzhou University,Lanzhou 730000,China;Heart Center,the First Hospital of Lanzhou University,Lanzhou 730000,China)

机构地区：[1]兰州大学第一临床医学院,兰州730000 [2]兰州大学第一医院心脏中心,兰州730000

出　　处：《医学综述》2023年第7期1297-1302,共6页Medical Recapitulate

基　　金：甘肃省科技计划项目-重点研发计划(21YF5FA118)。

摘　　要：心肌纤维化是心肌损伤后出现的病理性重塑,主要表现为富含胶原蛋白的细胞外基质过度沉积和纤维瘢痕形成,过度的心肌不良重塑最终导致心脏的收缩和舒张功能障碍,引起心律失常、心力衰竭等疾病。软骨中间层蛋白1(CILP-1)是一种细胞外基质蛋白,其主要发挥抗心肌纤维化的作用,但在特殊情况下也会促进心肌成纤维细胞增殖。CILP-1是一种可以便捷测量的生物标志物,相关临床试验结果也肯定了其作为心肌纤维化新型标志物的潜力,有望为心肌纤维化的预防和治疗提供新策略。Myocardial fibrosis is a pathological remodeling that occurs after myocardial injury,mainly manifested by excessive deposition of collagen-rich extracellular matrix and fibrous scar formation.Excessive poor myocardial remodeling eventually leads to systolic and diastolic dysfunction of the heart,causing arrhythmias,heart failure and other diseases.Cartilage intermediate layer protein 1(CILP-1)is an extracellular matrix protein that primarily acts as an anti-myocardial fibrosis agent,but may also promote myocardial fibroblast proliferation under specific circumstances.CILP-1 is a biomarker that can be easily measured,and relevant clinical trial results affirm its potential as a novel marker of myocardial fibrosis,and it is expected to provide new strategies for the prevention and treatment of myocardial fibrosis.

关 键 词：心肌纤维化 软骨中间层蛋白1 心肌成纤维细胞 肌成纤维细胞 转化生长因子-β信号通路 

分 类 号：R542.23[医药卫生—心血管疾病]